200 related articles for article (PubMed ID: 22824230)
21. High frequency of X4/DM-tropic viruses in PBMC samples from patients with primary HIV-1 subtype-B infection in 1996-2007: the French ANRS CO06 PRIMO Cohort Study.
Frange P; Galimand J; Goujard C; Deveau C; Ghosn J; Rouzioux C; Meyer L; Chaix ML
J Antimicrob Chemother; 2009 Jul; 64(1):135-41. PubMed ID: 19411680
[TBL] [Abstract][Full Text] [Related]
22. Mapping resistance to the CCR5 co-receptor antagonist vicriviroc using heterologous chimeric HIV-1 envelope genes reveals key determinants in the C2-V5 domain of gp120.
Ogert RA; Wojcik L; Buontempo C; Ba L; Buontempo P; Ralston R; Strizki J; Howe JA
Virology; 2008 Apr; 373(2):387-99. PubMed ID: 18190945
[TBL] [Abstract][Full Text] [Related]
23. Antiviral activity, pharmacokinetics and safety of vicriviroc, an oral CCR5 antagonist, during 14-day monotherapy in HIV-infected adults.
Schürmann D; Fätkenheuer G; Reynes J; Michelet C; Raffi F; van Lier J; Caceres M; Keung A; Sansone-Parsons A; Dunkle LM; Hoffmann C
AIDS; 2007 Jun; 21(10):1293-9. PubMed ID: 17545705
[TBL] [Abstract][Full Text] [Related]
24. Clonal analysis of HIV-1 genotype and function associated with virologic failure in treatment-experienced persons receiving maraviroc: Results from the MOTIVATE phase 3 randomized, placebo-controlled trials.
Lewis M; Mori J; Toma J; Mosley M; Huang W; Simpson P; Mansfield R; Craig C; van der Ryst E; Robertson DL; Whitcomb JM; Westby M
PLoS One; 2018; 13(12):e0204099. PubMed ID: 30586365
[TBL] [Abstract][Full Text] [Related]
25. Prevalence of R5 and X4 HIV variants in antiretroviral treatment experienced patients with virologic failure.
Ferrer P; Tello M; Montecinos L; Tordecilla R; Rodríguez C; Beltrán C; Guzmán MA; Ferrés M; Pérez CM; Afani A
J Clin Virol; 2014 Jul; 60(3):290-4. PubMed ID: 24793966
[TBL] [Abstract][Full Text] [Related]
26. Maraviroc is able to inhibit dual-R5 viruses in a dual/mixed HIV-1-infected patient.
Symons J; van Lelyveld SF; Hoepelman AI; van Ham PM; de Jong D; Wensing AM; Nijhuis M
J Antimicrob Chemother; 2011 Apr; 66(4):890-5. PubMed ID: 21393136
[TBL] [Abstract][Full Text] [Related]
27. Vicriviroc resistance decay and relative replicative fitness in HIV-1 clinical isolates under sequential drug selection pressures.
Tsibris AM; Hu Z; Paredes R; Leopold KE; Putcharoen O; Schure AL; Mazur N; Coakley E; Su Z; Gulick RM; Kuritzkes DR
J Virol; 2012 Jun; 86(12):6416-26. PubMed ID: 22491471
[TBL] [Abstract][Full Text] [Related]
28. High prevalence of X4/DM-tropic variants in children and adolescents infected with HIV-1 by vertical transmission.
Briz V; García D; Méndez-Lagares G; Ruiz-Mateos E; de Mulder M; Moreno-Pérez D; Navarro ML; León-Leal JA; de José MI; Ramos JT; Mellado MJ; González-Tomé MI; Leal M; Muñoz-Fernández MA
Pediatr Infect Dis J; 2012 Oct; 31(10):1048-52. PubMed ID: 22828644
[TBL] [Abstract][Full Text] [Related]
29. Genotypic analysis of human immunodeficiency virus type 1 env V3 loop sequences: bioinformatics prediction of coreceptor usage among 28 infected mother-infant pairs in a drug-naive population.
Duri K; Soko W; Gumbo F; Kristiansen K; Mapingure M; Stray-Pedersen B; Muller F;
AIDS Res Hum Retroviruses; 2011 Apr; 27(4):411-9. PubMed ID: 20969460
[TBL] [Abstract][Full Text] [Related]
30. Population-based V3 genotypic tropism assay: a retrospective analysis using screening samples from the A4001029 and MOTIVATE studies.
McGovern RA; Thielen A; Mo T; Dong W; Woods CK; Chapman D; Lewis M; James I; Heera J; Valdez H; Harrigan PR
AIDS; 2010 Oct; 24(16):2517-25. PubMed ID: 20736814
[TBL] [Abstract][Full Text] [Related]
31. The impact of HIV tropism on decreases in CD4 cell count, clinical progression, and subsequent response to a first antiretroviral therapy regimen.
Waters L; Mandalia S; Randell P; Wildfire A; Gazzard B; Moyle G
Clin Infect Dis; 2008 May; 46(10):1617-23. PubMed ID: 18419499
[TBL] [Abstract][Full Text] [Related]
32. In vivo emergence of vicriviroc resistance in a human immunodeficiency virus type 1 subtype C-infected subject.
Tsibris AM; Sagar M; Gulick RM; Su Z; Hughes M; Greaves W; Subramanian M; Flexner C; Giguel F; Leopold KE; Coakley E; Kuritzkes DR
J Virol; 2008 Aug; 82(16):8210-4. PubMed ID: 18495779
[TBL] [Abstract][Full Text] [Related]
33. Primary resistance of CCR5-tropic HIV-1 to maraviroc cannot be predicted by the V3 sequence.
Delobel P; Cazabat M; Saliou A; Loiseau C; Coassin L; Raymond S; Requena M; Marchou B; Massip P; Izopet J
J Antimicrob Chemother; 2013 Nov; 68(11):2506-14. PubMed ID: 23794603
[TBL] [Abstract][Full Text] [Related]
34. Vicriviroc: a CCR5 antagonist for treatment-experienced patients with HIV-1 infection.
Kümmerle T; Lehmann C; Hartmann P; Wyen C; Fätkenheuer G
Expert Opin Investig Drugs; 2009 Nov; 18(11):1773-85. PubMed ID: 19888873
[TBL] [Abstract][Full Text] [Related]
35. Deep sequencing to infer HIV-1 co-receptor usage: application to three clinical trials of maraviroc in treatment-experienced patients.
Swenson LC; Mo T; Dong WW; Zhong X; Woods CK; Jensen MA; Thielen A; Chapman D; Lewis M; James I; Heera J; Valdez H; Harrigan PR
J Infect Dis; 2011 Jan; 203(2):237-45. PubMed ID: 21288824
[TBL] [Abstract][Full Text] [Related]
36. Evolution of CCR5 antagonist resistance in an HIV-1 subtype C clinical isolate.
Henrich TJ; Tsibris AM; Lewine NR; Konstantinidis I; Leopold KE; Sagar M; Kuritzkes DR
J Acquir Immune Defic Syndr; 2010 Dec; 55(4):420-7. PubMed ID: 20856130
[TBL] [Abstract][Full Text] [Related]
37. HIV type 1 chemokine coreceptor use among antiretroviral-experienced patients screened for a clinical trial of a CCR5 inhibitor: AIDS Clinical Trial Group A5211.
Wilkin TJ; Su Z; Kuritzkes DR; Hughes M; Flexner C; Gross R; Coakley E; Greaves W; Godfrey C; Skolnik PR; Timpone J; Rodriguez B; Gulick RM
Clin Infect Dis; 2007 Feb; 44(4):591-5. PubMed ID: 17243065
[TBL] [Abstract][Full Text] [Related]
38. Phase 2 study of the safety and efficacy of vicriviroc, a CCR5 inhibitor, in HIV-1-Infected, treatment-experienced patients: AIDS clinical trials group 5211.
Gulick RM; Su Z; Flexner C; Hughes MD; Skolnik PR; Wilkin TJ; Gross R; Krambrink A; Coakley E; Greaves WL; Zolopa A; Reichman R; Godfrey C; Hirsch M; Kuritzkes DR;
J Infect Dis; 2007 Jul; 196(2):304-12. PubMed ID: 17570119
[TBL] [Abstract][Full Text] [Related]
39. Virologic failure in first-line human immunodeficiency virus therapy with a CCR5 entry inhibitor, aplaviroc, plus a fixed-dose combination of lamivudine-zidovudine: nucleoside reverse transcriptase inhibitor resistance regardless of envelope tropism.
Demarest JF; Amrine-Madsen H; Irlbeck DM; Kitrinos KM;
Antimicrob Agents Chemother; 2009 Mar; 53(3):1116-23. PubMed ID: 19075055
[TBL] [Abstract][Full Text] [Related]
40. HIV-2 A-subtype gp125c₂-v₃-c₃ mutations and their association with CCR5 and CXCR4 tropism.
Dimonte S; Svicher V; Salpini R; Ceccherini-Silberstein F; Perno CF; Babakir-Mina M
Arch Virol; 2011 Nov; 156(11):1943-51. PubMed ID: 21814863
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
